Mini Review Open Access
Volume 3 | Issue 1 | DOI: https://doi.org/10.33696/immunology.3.070

Gene Knock-in Strategy for Engineered T-cell Therapy

  • 1BGI-Shenzhen, Shenzhen 518083, China
  • 2Guangdong Provincial Key Laboratory of Human Disease Genomics, Shenzhen Key Laboratory of Genomics
  • 3BGI Education Center, University of Chinese Academy of Sciences, Shenzhen 518083, China
  • #These authors contributed equally
+ Affiliations - Affiliations

Corresponding Author

Cheng-Chi Chao, great_scientist@yahoo.com; Qianqian Gao, gaoqq@szbl.ac.cn

Received Date: September 29, 2020

Accepted Date: November 23, 2020


Genetically engineered T-cell therapy holds great potential for the curative treatment across a series of cancers. However, drug-related safety concerns need to be addressed in the emerging medicine of the future. T cells are engineered through conventional methods like lentivirus, retrovirus or transposon, which randomly integrate exogenous gene cassette into T cell genome, accompanied by the risks of transcriptional silencing, oncogenesis, and variegated transgene expression. The development of robust gene-editing tools makes it possible to efficiently insert designed DNA fragments into specific locus of T cell genome, which lowers the risks caused by random integration. The authors review existing gene-editing tools for T cell engineering, and further discuss the next generation of CAR-T platforms for efficient delivery of gene-editing cargo into the target cells.

Author Information X